Aib substitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-08 and is reviewed periodically as new material appears.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
GnRH antagonists (receptor blockers) such as degarelix are synthetic peptide derivatives of the natural GnRH decapeptide – a hormone that is made by neurons in the hypothalamus. GnRH antagonists compete with natural GnRH for binding to GnRH receptors in the pituitary gland. This reversible binding blocks the release of LH and FSH from the pituitary. The reduction in LH subsequently leads to a rapid and sustained suppression of testosterone release from the testes and subsequently reduces the size and growth of the prostate cancer. This in turn results in a reduction in prostate-specific antigen (PSA) levels in the patient's blood. Measuring PSA levels helps to monitor how patients with prostate cancer are responding to treatment. Unlike GnRH agonists, which cause an initial stimulation of the hypothalamic-pituitary-gonadal axis (HPGA), leading to a surge in testosterone levels, and under certain circumstances, a flare-up of the tumour, GnRH antagonists do not cause a surge in testosterone or clinical flare. Clinical flare is a phenomenon that occurs in patients with advanced disease, which can precipitate a range of clinical symptoms such as bone pain, urethral obstruction, and spinal cord compression. Drug agencies have issued boxed warnings regarding this phenomenon in the prescribing information for GnRH agonists. As testosterone surge does not occur with GnRH antagonists, there is no need for patients to receive an antiandrogen as flare protection during prostate cancer treatment.
The norepinephrine transporter is composed of 12 transmembrane domains (TMDs). The intracellular portion contains an amino (-NH2) group and carboxyl (-COOH) group. In addition, there is a large extracellular loop located between TMD 3 and 4. The protein is composed of 617 amino acids.
A report by the Public Accounts Committee finds that only 10% of the money promised to reduce inequality under the Levelling Up scheme had actually been spent. The Animal Welfare (Import of Dogs, Cats and Ferrets) Bill, introduced as a private member's bill, passes its first reading in the House of Commons after securing the backing of the UK government. The bill aims to ban the import of puppies, kittens and ferrets under the age of six months into the UK. Apple agrees to pay a £385m settlement on a lawsuit led by Norfolk County Council, which was started over allegations Apple CEO Tim Cook defrauded shareholders in a pension company administered by the Council by covering up lower demand for iPhones in China. 16 March – Vaughan Gething is elected to lead Welsh Labour, and will become First Minister of Wales. He will be Wales's first black leader, and the first black person to lead a country in Europe. With Gething's win it means that three of the four governments in the UK will have non-white leaders. A group calling itself the South Devon Primary, which aims to unseat Conservative MPs in South Devon at the next election, chooses Liberal Democrat Caroline Voaden as a candidate for one of its constituencies. Traditional Unionist Voice leader Jim Allister announces a formal "partnership" with Reform UK at the next general election. 17 March – Transport Secretary Mark Harper tells the BBC that the Conservative Party welcomes members "whatever their race".
where a deuteron hitting uranium-238 produces two neutrons and neptunium-238, which decays by emitting negative beta particles to form plutonium-238. Plutonium-238 can also be produced by neutron irradiation of neptunium-237.
== Other animals == Bovine somatotropin occurs in the pituitary of cattle and differs in structure from human pituitary growth hormone and is biologically inactive in the human being. Bovine somatotropin aids in regulating the amount of milk produced. Recombinant bovine somatotropin (rBST) is a hormone that is injected in cows that increases milk production.
Sources: en.wikipedia.org
Sheikh Hazza bin Zayed bin Sultan Al Nahyan (Arabic: هزاع بن زايد بن سلطان آل نهيان; born 2 June 1965) is the younger brother of the President of the United Arab Emirates Sheikh Mohamed bin Zayed Al Nahyan, Ruler's Representative of Al Ain Region of the Emirate of Abu Dhabi, former National Security Advisor of the UAE and Deputy Chairman of Abu Dhabi Executive Council.
=== Breast cancer === Breast cell proliferation has been found to be significantly increased by the combination of an oral estrogen plus cyclic medroxyprogesterone acetate in postmenopausal women but not by the combination of transdermal estradiol plus oral progesterone. Studies of topical estradiol and progesterone applied to the breasts for 2 weeks have been found to result in highly pharmacological local levels of estradiol and progesterone. These studies have assessed breast proliferation markers and have found increased proliferation with estradiol alone, decreased proliferation with progesterone, and no change in proliferation with estradiol and progesterone combined. In the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, the combination of estrogen and cyclic oral progesterone resulted in a higher mammographic breast density than estrogen alone (3.1% vs. 0.9%) but a non-significantly lower breast density than the combination of estrogen and cyclic or continuous medroxyprogesterone acetate (3.1% vs. 4.4–4.6%). Higher breast density is a strong known risk factor for breast cancer. Other studies have had mixed findings however. A 2018 systematic review reported that breast density with an estrogen plus oral progesterone was significantly increased in three studies and unchanged in two studies. Changes in breast density with progesterone appear to be less than with the compared progestins.
== Tissue distribution == Studies have detected FFAR2 protein and/or its messenger RNA (an indicator of FFAR2 protein expression) in the following cell types, cell lines, and tissues: 1) human and rodent enteroendocrine K cells, i.e., cells located in the epithelium of the small intestine; 2) human and rodent enteroendocrine L cells, i.e., cells located in the epithelium of the small intestine and colon; 3) human and rodent fat tissue and/or cultured fat cells; 4) cells in human and rodent pancreatic islets (these islets contain the beta cells and alpha cells that synthesize and secrete insulin and glucagon, respectively, into the blood); 5) cells in and/or derived from cells in the human or mouse spleen, lymph nodes, bone marrow, and blood (e.g., monocytes, lymphocytes, and neutrophils); 6) mouse and, based on indirect studies, human dendritic cells; 7) cells in or derived from cells in human and/or rodent kidneys, hearts, brains (e.g., hypothalamus), fetal membranes, and placentas; 8) cells in the taste buds' lingual papillae of human tongues; 9) mouse renal arteries, aortas, and iliac arteries; 10) various human cell lines including SW480, SW620, HT-29, and T84 colon cancer cells, NCI-H716 colon cancer cells that have a lymphoblast morphology, Caco-2 colorectal cancer cells, Hutu-80 duodenal cancer cells, SW872 liposarcoma cells, MDA-MB-231, MDA-MB-436, and MCF7 breast cancer cells, Huh7 and JHH-4 liver cancer cells, THP-1 acute myeloid leukemia cells, U937 acute promyelocytic leukemia cells, and K562 myelogenous leukemia cells; and 11) the various mouse and rat cell lines discussed below. FFAR2 is also expressed in a wide range of tissues in other animals such as cows, pigs, sheep, cats, and dogs.
Recent economic growth has led to a considerable increase of new millionaires, including the new entrepreneurs, Colombians with a net worth exceeding US$1 billion. In 2017, however, the National Administrative Department of Statistics (DANE) reported that 26.9% of the population were living below the poverty line, of which 7.4% were in "extreme poverty". The multidimensional poverty rate stands at 17.0 percent of the population. The Government has also been developing a process of financial inclusion within the country's most vulnerable population. The contribution of tourism to GDP was US$5,880.3bn (2.0% of total GDP) in 2016. Tourism generated 556,135 jobs (2.5% of total employment) in 2016. Foreign tourist visits were predicted to have risen from 0.6 million in 2007 to 4 million in 2017.
In Buddhism and Art in Gandhāra and Kucha: Buddhist Culture along the Silk Road; Gandhāra, Kucha, and Turfan, Section I, edited by Miyaji Akira, pp. 125–63. Kyoto: Ryukoku University. Howard, Angela Falco; Vignato, Giuseppe (2015). Archaeological and Visual Sources of Meditation in the Ancient Monasteries of Kuca. Leiden: Brill. ISBN 9789004278578. Le Coq, Albert von (1913). Chotscho: Facsimile-Wiedergaben der wichtigsten Funde der 1. Kgl. Preuss. Expedition nach Turfan in Ostturkistan. Berlin. (1982). Along the ancient silk routes: Central Asian art from the West Berlin State Museums. Exhibition from the Museum für Indische Kunst, Staatliche Museen Preussischer Kulturbesitz, Berlin and Federal Republic of Germany at the Metropolitan Museum of Art, New York. Morita, Miki (2015). "The Kizil Paintings in the Metropolitan Museum" in The Metropolitan Museum Journal, vol. 50, pp. 115–136. Vignato, Giuseppe (2006). "Archaeological Survey of Kizil, Its Groups of Caves, Districts, Chronology and Buddhist Schools" in East and West (Rome) 56/4: 359–416. Zin, Monika (2007). "The Identification of the Kizil Paintings II [3. Sudåya, 4. Brhaddyuti]" in Indo-Asiatische Zeitschrift (Berlin) 11: 43–52. Encyclopedia of Buddhist Art 世界佛教美術圖說大辭典. FGS. Archived from the original on 2021-01-21. Retrieved 2021-01-27.
Sources: en.wikipedia.org
The definition of whistleblowing in force under the "Sapin 2 Law" – which includes whistleblowing not based on work – has been maintained. The protection applies to any natural person who facilitates or assists whistleblowers – as required in the directive – but also to entities such as NGOs (Non-governmental organizations) or trade unions, which act as a facilitator. They are offered the same level of protection. Military personnel will now be afforded the same level of protection as other civil servants, so long as they do not disclose information that may harm national security. The law provides that whistleblowers may be granted financial assistance when subjected to a suit, by making an application to a judge, who has the power to force the suing organization – the employer, for instance – to cover their legal fees and, if their financial situation has deteriorated, their living expenses. The law provides that whistleblowers shall not incur criminal liability with respect to the acquisition of, or access to, the information that is reported or publicly disclosed. They cannot be sentenced for any offenses committed to gather proof or information as long as they obtained it lawfully. The law strengthens existing sanctions against those who retaliate against whistleblowers: The criminal sanctions applicable to persons retaliating against whistleblowers can go up to three years of imprisonment and a fine of €45,000. The judges may impose €60,000 fines on companies taking a SLAPP action against a whistleblower.
In 1995, the Insurance Institute for Highway Safety (IIHS) began frontal offset crash tests. Also in the same year, Volvo introduced the world's first car with side airbags: the 850. In 1996, the European New Car Assessment Programme (Euro NCAP) was established to test new vehicles' safety performance and publish the results for vehicle shoppers' information. The NHTSA crash tests are presently operated and published as the U.S. branch of the international NCAP programme.
C-5 sterol desaturase catalyzes an intermediate step in the synthesis of major sterols. The particular biosynthetic pathway varies across eukaryotes. In animals C5SD catalyzes the dehydration of lathosterol to 7-dehydrocholesterol, a step in the synthesis of cholesterol. Cholesterol serves multiple roles in the cell including modulating membrane fluidity serving as a precursor to steroid hormones. In fungi C5SD catalyzes the dehydration of episterol as a step in the synthesis of ergosterol, a sterol that regulates cell membrane fluidity and permeability. In plants such as Arabidopsis thaliana, C-5 sterol desaturase catalyzes the dehydrogenation of episterol and avenasterol in a pathway thought to lead to a variety of membrane components as well as a class of hormones called brassinosteroids.
The addition of 1% cerium dioxide, as in gas mantles, heightens the effect by increasing emissivity in the visible region of the spectrum; but because cerium, unlike thorium, can occur in multiple oxidation states, its charge and hence visible emissivity will depend on the region on the flame it is found in (as such regions vary in their chemical composition and hence how oxidising or reducing they are). Several binary thorium chalcogenides and oxychalcogenides are also known with sulfur, selenium, and tellurium. All four thorium tetrahalides are known, as are some low-valent bromides and iodides: the tetrahalides are all 8-coordinated hygroscopic compounds that dissolve easily in polar solvents such as water. Many related polyhalide ions are also known. Thorium tetrafluoride has a monoclinic crystal structure like those of zirconium tetrafluoride and hafnium tetrafluoride, where the Th4+ ions are coordinated with F− ions in somewhat distorted square antiprisms. The other tetrahalides instead have dodecahedral geometry. Lower iodides ThI3 (black) and ThI2 (gold-coloured) can also be prepared by reducing the tetraiodide with thorium metal: they do not contain Th(III) and Th(II), but instead contain Th4+ and could be more clearly formulated as electride compounds. Many polynary halides with the alkali metals, barium, thallium, and ammonium are known for thorium fluorides, chlorides, and bromides.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.